NeoImmuneTech Inc (KOSDAQ: 950220), a US-based clinical-stage T cell-focused biopharmaceutical company, announced on Tuesday that it has named Luke Oh, PhD as its new president and chief executive officer (CEO).
Dr Oh is to succeed Dr Se Hwan Yang, PhD. In the new role, Dr. Oh will head the company from its Rockville headquarters and oversee all of the company's Korea operations.
With more than six years of regulatory experience at the US FDA, Dr Oh has also served as vice-president in charge of Regulatory Development at Samsung Bioepis, senior staff fellow at the US FDA Division of Clinical Pharmacology III and Division of Inflammation and Immune Pharmacology, and in various roles in research and development for leading organisations such as Mallinckrodt Pharmaceuticals, Human Genome Sciences and Vertex Pharmaceuticals.
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline